Enrolling by invitation

Vagus Nerve Stimulation Devices for Somatic Symptom Disorder

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

gammaCore Sapphire

+ Nurosym

Device
Who is being recruted

Anxiety Disorders+2

+ Behavior

+ Mental Disorders

From 18 to 65 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: November 2025
See protocol details

Summary

Principal SponsorNational Taiwan University Hospital
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 17, 2025

Actual date on which the first participant was enrolled.

This study aims to help people with Somatic Symptom Disorder (SSD) by comparing two types of non-invasive treatments that target the vagus nerve, which plays a crucial role in regulating bodily functions and stress responses. People with SSD often experience intense physical symptoms and health anxiety that lack a clear medical cause, leading to significant distress. By evaluating two specific devices, gammaCore and Nurosym, that stimulate different parts of the vagus nerve, the study hopes to find an effective way to reduce the severity of these symptoms and improve the quality of life for individuals affected by SSD. Participants in the study will use both devices in a specific sequence during the trial period. The gammaCore device stimulates the vagus nerve in the neck, while the Nurosym device targets the ear's vagus nerve area. Each device will be used for a set number of daily sessions over two weeks, with breaks in between to ensure safety. Researchers will measure changes in physical symptoms and health anxiety through questionnaires to determine the effectiveness of each treatment. Additional aspects like depression, anxiety, and physiological responses will also be monitored to assess any further benefits or side effects. Safety is closely monitored throughout the study to ensure the well-being of all participants.

Official TitleTreatment of Somatic Symptom Disorder With Transcutaneous Cervical Vagus Nerve Stimulation and Transcutaneous Auricular Vagus Nerve Stimulation: A Crossover Randomized Controlled Trial
NCT07198542
Principal SponsorNational Taiwan University Hospital
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

60 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Anxiety DisordersBehaviorMental DisordersBehavioral SymptomsDepression

Criteria

Inclusion Criteria: 1. Meets the diagnostic criteria for Somatic Symptom Disorder (SSD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), as determined by a diagnostic interview with a board-certified psychiatrist. 2. The participant must be receiving stable, routine medical care throughout the trial period. 3. No adjustments to psychiatric or cardiovascular medications for at least one week prior to the start of the study. Exclusion Criteria: 1. Age below 18 or above 65 years. 2. Presence of psychotic symptoms, such as in comorbid schizophrenia. 3. Significant cognitive impairment (e.g., diagnosed dementia or intellectual disability) or difficulty completing the study questionnaires. 4. History of cervical vagotomy. 5. Presence of severe cardiovascular diseases, including: clinically significant tachycardia (resting heart rate \>100 bpm) or bradycardia (resting heart rate \<60 bpm); clinically significant hypertension (systolic \>160 mmHg or diastolic \>100 mmHg) or hypotension (blood pressure \<90/60 mmHg or mean arterial pressure \<65 mmHg); severe coronary artery disease; carotid atherosclerosis or stenosis; aneurysm; congestive heart failure; severe cardiac arrhythmias (e.g., prolonged QT interval, second- or third-degree atrioventricular block, atrial fibrillation, atrial flutter, recent ventricular tachycardia or fibrillation, clinically significant premature ventricular contractions); or myocardial infarction within the last five years. 6. Presence of severe neurological conditions, including severe head trauma, history of epilepsy, brain tumor, or cerebral hemorrhage. 7. Current diagnosis of cancer. 8. Presence of any active implanted medical devices (e.g., cochlear implant, ventricular shunt, implantable vagus nerve stimulator, pacemaker) or non-active implants that may interact with the nervous system (e.g., metal stents, bone plates, screws). 9. Anatomical abnormalities in the neck. 10. Currently pregnant. 11. Wearing jewelry near the tragus that cannot be removed before using the tVNS device. 12. Severe skin disease at the stimulation sites. 13. Known allergy to conductive gel materials. 14. Any other major medical condition that, in the investigator's judgment, could potentially affect the safety or efficacy of vagus nerve stimulation.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Participants assigned to this sequence will first receive active transcutaneous cervical vagus nerve stimulation (tcVNS) using the gammaCore device. This initial treatment period consists of 10 daily sessions (approx. 20 minutes each) over 2 weeks, followed by a 1-week follow-up assessment. After a 1-week washout period, participants will cross over to the second treatment period. In this period, they will receive active transcutaneous auricular vagus nerve stimulation (taVNS) using the Nurosym device for 10 daily 30-minute sessions over 2 weeks, followed by a final 1-week follow-up assessment.

Group II

Experimental
Participants assigned to this sequence will first receive active transcutaneous auricular vagus nerve stimulation (taVNS) using the Nurosym device. This initial treatment period consists of 10 daily 30-minute sessions over 2 weeks, followed by a 1-week follow-up assessment. After a 1-week washout period, participants will cross over to the second treatment period. In this period, they will receive active transcutaneous cervical vagus nerve stimulation (tcVNS) using the gammaCore device for 10 daily sessions (approx. 20 minutes each) over 2 weeks, followed by a final 1-week follow-up assessment.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Department of Psychiatry, National Taiwan University Hospital Yunlin Branch

Douliu, Yunlin, TaiwanOpen Department of Psychiatry, National Taiwan University Hospital Yunlin Branch in Google Maps
Enrolling by invitationOne Study Center